The global ankylosing spondylitis treatment market is witnessing significant growth, with projections indicating a market value of USD 8.06 billion in 2022 and an expected increase to USD 5.1409 billion by 2032. This translates to a compound annual growth rate (CAGR) of 4.6% over the forecast period, reflecting advancements in treatment modalities and a deeper understanding of this chronic inflammatory condition.
Ankylosing spondylitis primarily affects the spine, leading to debilitating pain and stiffness. Recent years have seen remarkable therapeutic innovations, particularly in the development of Tumor Necrosis Factor (TNF) inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). These treatments have emerged as pivotal solutions not only for managing ankylosing spondylitis but also for addressing a range of other inflammatory arthritis conditions. This shift signifies a commitment to enhancing patient outcomes and improving overall quality of life.
Despite these advancements, the market faces ongoing challenges, as highlighted by recent studies and findings. The treatment landscape continues to evolve, emphasizing the need for sustained research and development efforts to address unmet needs and optimize treatment efficacy.
“We are witnessing a transformative phase in the management of ankylosing spondylitis,” stated a representative from FMI. “As market leaders, we remain committed to driving innovation and delivering solutions that make a meaningful difference in the lives of patients worldwide.”
As the market continues to grow, stakeholders in the ankylosing spondylitis treatment space are urged to collaborate and invest in research initiatives to further enhance treatment options and improve patient care.
Key Takeaways from Ankylosing Spondylitis Treatment Market Study:
- Nonsteroidal anti-inflammatory drugs lead the market as they are looked upon as the first line of treatment for ankylosing spondylitis
- Oral route of administration holds the largest market share due to simplicity of consumption.
- By age group, “adults” contribute to majority of revenue generation as ankylosing spondylitis usually gets initiated in adulthood.
- North America, led by the US, holds the highest market share due to well-established healthcare infrastructure, high incidences of ankylosing spondylitis, and innovations in pharmaceutical industry.
Ankylosing Spondylitis Treatment Market Trends:
The healthcare sector is increasingly focused on advancing research into ankylosing spondylitis, aiming to drive innovation forward.
For example:
- In July 2020, researchers at Rockefeller University identified “PRIME cells” capable of suppressing inflammation associated with rheumatoid arthritis, offering potential insights into managing flares of this condition. This breakthrough is expected to pave the way for the development of biosimilars to treat such forms of spondylitis before they progress to advanced stages.
- In June 2020, Celltrion Healthcare received a recommendation from the Committee for Medicinal Products for Human Use (CHMP) for the use of Remsima in ankylosing spondylitis.
- In October 2019, the Spondylitis Association of America (SAA) partnered with PatientPoint to enhance education about spondylitis and support rheumatology practices across the United States.
Major Players in the Ankylosing Spondylitis Treatment Market:
- Wyeth
- Mitsubishi Tanabe
- Schering-Plough
- Takeda
- Amgen
- Centocor
- Abbott
- Eisai
- Pfizer
Key Segment:
Drug Class
- Nonsteroidal Anti-inflammatory Drugs
- Anti-Inflammatory Drugs
- Immunosuppressive Drugs
- TNF Blockers
- JAK Inhibitors
- Steroids
- Biologics
- Others
Route of Administration
- Parenteral
- Oral
Application
- Adults
- Juveniles
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube